BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 10458260)

  • 1. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin.
    Go RS; Adjei AA
    J Clin Oncol; 1999 Jan; 17(1):409-22. PubMed ID: 10458260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin versus cisplatin in solid tumors: an analysis of the literature.
    Lokich J; Anderson N
    Ann Oncol; 1998 Jan; 9(1):13-21. PubMed ID: 9541678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer.
    Jiang J; Liang X; Zhou X; Huang R; Chu Z
    Lung Cancer; 2007 Sep; 57(3):348-58. PubMed ID: 17485133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer.
    Hotta K; Matsuo K; Ueoka H; Kiura K; Tabata M; Tanimoto M
    J Clin Oncol; 2004 Oct; 22(19):3852-9. PubMed ID: 15326195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity of platinum compounds.
    Hartmann JT; Lipp HP
    Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cisplatin or carboplatin, that is the question].
    Moncharmont C; Auberdiac P; Mélis A; Afqir S; Pacaut C; Chargari C; Merrouche Y; Magné N
    Bull Cancer; 2011 Feb; 98(2):164-75. PubMed ID: 21382796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of carboplatin].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 1990 Sep; 17(9):1949-58. PubMed ID: 2203318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future role of carboplatin.
    Ruckdeschel JC
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):114-8. PubMed ID: 7992063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis.
    Ardizzoni A; Boni L; Tiseo M; Fossella FV; Schiller JH; Paesmans M; Radosavljevic D; Paccagnella A; Zatloukal P; Mazzanti P; Bisset D; Rosell R;
    J Natl Cancer Inst; 2007 Jun; 99(11):847-57. PubMed ID: 17551145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
    Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
    Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced ovarian cancer. Carboplatin versus cisplatin.
    Vermorken JB; ten Bokkel Huinink WW; Eisenhauer EA; Favalli G; Belpomme D; Conte PF; Kaye SB
    Ann Oncol; 1993; 4 Suppl 4():41-8. PubMed ID: 8312200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative clinical pharmacology of cisplatin and carboplatin.
    Murry DJ
    Pharmacotherapy; 1997; 17(5 Pt 2):140S-145S. PubMed ID: 9322881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature.
    D'Addario G; Pintilie M; Leighl NB; Feld R; Cerny T; Shepherd FA
    J Clin Oncol; 2005 May; 23(13):2926-36. PubMed ID: 15728229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Carboplatin in cancer of the ovary].
    Pujade-Lauraine E; Guastalla JP; Vincent P
    Bull Cancer; 2000 Aug; 87 Spec No():40-7. PubMed ID: 11082722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
    Belani CP
    Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative chemoradiotherapy for high-risk head-and-neck squamous cell carcinoma.
    Porceddu SV; Campbell B; Rischin D; Corry J; Weih L; Guerrieri M; Grossi M; Peters LJ
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):365-73. PubMed ID: 15380568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies.
    Ho GY; Woodward N; Coward JI
    Crit Rev Oncol Hematol; 2016 Jun; 102():37-46. PubMed ID: 27105947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.